Laminin c2 (Lmc2) chain, a subunit of laminin-332, is a typical molecular marker of invading cancer cells, and its expression correlates with poor prognosis of cancer patients. It was previously found that forced expression of Lmc2 in cancer cells promotes their invasive growth in nude mice. However, the mechanism of the tumor-promoting activity of Lmc2 remains unknown. Here we investigated the interaction between Lmc2 and vascular endothelial cells. When treated with an N-terminal proteolytic fragment of c2 (c2pf), HUVECs became markedly retracted or shrunken. The overexpression of Lmc2 or treatment with c2pf stimulated T-24 bladder carcinoma cells to invade into the HUVEC monolayer and enhanced their transendothelial migration in vitro. Moreover, c2pf increased endothelial permeability in vitro and in vivo. As the possible mechanisms, c2pf activated ERK and p38 MAPK but inactivated Akt in HUVECs. Such effects of c2pf led to prominent actin stress fiber formation in HUVECs, which was blocked by a ROCK inhibitor. In addition, c2pf induced delocalization of VE-cadherin and b-catenin from the intercellular junction. As possible receptors, c2pf interacted with heparan sulfate proteoglycans on the surface of HUVECs. Moreover, we localized the active site of c2pf to the N-terminal epidermal growth factor-like repeat. These data suggest that the interaction between c2pf and heparan sulfate proteoglycans induces cytoskeletal changes of endothelial cells, leading to the loss of endothelial barrier function and the enhanced transendothelial migration of cancer cells. These activities of Lmc2 seem to support the aberrant growth of cancer cells. E pithelial tissues are separated from connective tissues by thin membrane structures called basement membranes. Loss of this structure is closely associated with cancer progression. Laminins, large glycoproteins composed of a, b, and c chains, are essential components of various basement membranes.
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(1) Seventeen laminin isoforms with different combinations of three chains (a1-a5, b1-b3, and c1-c3), including a recently identified vascular-type laminin (laminin-3B11), have been identified so far. (2, 3) Among the laminin families, laminin-332 (Lm332) consisting of a3, b3, and c2 chains, previously known as laminin-5, is a major type of laminin in epithelial tissues. (4) (5) (6) In the skin, Lm332 is an essential component of hemidesmosomes and stably anchors basal keratinocytes to the basement membrane. (5, 7) We initially identified Lm332 as a cancer cell-derived scatter factor that strongly stimulates cell adhesion and migration. (8) Indeed, unlike other types of laminins, a soluble form of Lm332 stimulates cell migration. (9) The cell adhesion and motility activities of Lm332 are regulated by the proteolytic cleavage of the short arm of laminin c2 (Lmc2) chain. (10, 11) Metalloproteinases such as BMP-1 and MT1-MMP have been reported to cleave Lmc2 at its N-terminal short arm. (12, 13) Recent studies have shown that the N-terminal region of Lmc2 is essential for the assembly of Lm332 into extracellular matrix. (14) Laminin-332 matrix assembled by cultured cells stably anchors cells, whereas a soluble form of Lm332 highly promotes cell migration. (15) Because of the unique properties of Lm332, much attention has been focused on its possible roles in cancer malignancy. (16) (17) (18) (19) Laminin-332 is found in basement membranes of many types of differentiated carcinomas. A number of immunohistochemical studies have shown that Lm332 or its subunits are overexpressed in invasive human carcinomas. (20) In particular, Lmc2 is overexpressed at invasion fronts of many types of human cancers such as colorectum, (21, 22) pancreas, (23) stomach, (24) lung, (25) and esophagus. (26) Such characteristic expression of the Lmc2 chain is associated with poor prognosis and metastasis. (23, 26, 27) Thus, Lmc2 has been regarded as a typical molecular marker of invasive carcinomas. Our past studies have shown that Lmc2 is expressed mainly as a monomer form, but not as the Lm332 heterotrimer, by invading carcinomas cells. (24, 25) In human cell culture, excess Lmc2 is secreted as the monomer or the b3 ⁄ c2 heterodimer into culture medium, (15, 28, 29) and its short arm fragment is released into circulation of patients with head and neck squamous cell carcinomas. (30) Expression of Lmc2 is regulated together with MT1-MMP by Wint-b-catenin signaling (22) and stimulated by epidermal growth factor (EGF), tumor necrosis factor-a, and transforming growth factor-b in association with the epithelial-mesenchymal transition of human carcinoma cells. (28, 31) The characteristic expression and localization of Lmc2 suggest that Lmc2 monomer, apart from Lm332, has some special roles in tumor invasion. We recently found that forced overexpression of the Lmc2 monomer or its short arm (c2SA) in T-24 human bladder carcinoma cells promotes their invasive growth in nude mice. (28) However, the mechanism by which Lmc2 promotes tumor invasion remains totally unknown.
It has well been established that stromal tissues surrounding cancer cells, such as fibroblasts, inflammatory cells, and vascular endothelial cells, are deeply involved in tumor progression. (32) In particular, tumor angiogenesis plays critical roles in tumor growth, invasion, and metastasis. (33) (34) (35) In this study, we investigated the possibility that Lmc2 might have some activity towards vascular endothelial cells. Our results show that Lmc2 induces retraction of vascular endothelial cells and enhances vascular permeability in vitro and in vivo. Cell culture. The human bladder carcinoma cell line T-24 (EJ-1 strain) and its transfectants (Mock-T24 and c2SA-T24) were used in our previous study. (28) These cells were maintained in DMEM ⁄ F12 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS (Nichirei Biosciences, Tokyo, Japan) and antibiotics. Human umbilical vein endothelial cells were purchased from Kurabo (Osaka Japan) and maintained on type I collagen (40 lg ⁄ mL) (Nitta Gelatin, Osaka, Japan) coated plates in MCDB131 medium (Sigma-Aldrich) supplemented with 10 ng ⁄ mL EGF (Wako, Osaka Japan), 5 ng ⁄ mL basic fibroblast growth factor (Wako), 50 lg ⁄ mL heparin (Wako), 10% FCS, and antibiotics.
Preparation of recombinant proteins. Recombinant proteins of Lmc2 and its fragments, c2 proteolytic fragment (c2pf) and c2 domain V (c2dV), all of which contained the His-tag sequence in their C-termini, were prepared as previously reported. (36) Expression vectors for three deletion mutants of c2dV with His-tag, named NE1 ⁄ 2, NE1 ⁄ 3 and NE2 ⁄ 3, were constructed with the pSecTag2B ⁄ Zeo vector (Invitrogen). The expression vectors were transfected into human embryonic kidney cell line HEK293 using the X-tremeGENE 9 DNA transfection reagent (Roche, Basel, Switzerland). Each protein was purified from the conditioned medium of the stable transfectants using cOmplete His-Tag Purification Resin (Roche). The detailed methods for the construction of the c2-expression vectors and the protein purification are described in Document S1.
In vitro and in vivo endothelial permeability assays. The in vitro permeability assay was carried out using the twochamber methods reported by Chen et al. (37) Briefly, a HUVEC monolayer that had been prepared on type I collagencoated culture insert (0.4-lm pore size; BD Bioscience) was treated with test proteins in the growth medium for 18 h and then with FITC-dextran (40 kDa; Sigma-Aldrich) for 3 h. The amount of FITC-dextran diffused into the lower chamber was measured by excitation at 485 nm and emission at 590 nm. Miles vascular permeability assay was carried out using the BALB ⁄ c strain of mice (5-6 weeks old) essentially by the method of Zhang et al. (38) All mice were handled according to the recommendations of the National Institutes of Health Guidelines for Care and Use of Laboratory Animals. The experimental protocol was approved by the Animal Care Committee of Kihara Institute for Biological Research (Yokohama, Japan). Evans blue dye (200 lL of a 0.5% solution in 0.9% NaCl) was injected i.v. into each mouse. Ten minutes later, 50 lL of test samples were injected intradermally into the back skin. Phosphate-buffered saline, as the vehicle control, and test samples were injected into separate points of the same mouse. Thirty minutes later, the animals were killed, and the skin area that covered the entire injection site was removed by punch biopsies. Evans blue dye diffused from blood vessels was extracted from the resected skin tissues and measured for absorbance at 595 nm.
Assays of T-24 cell invasion into endothelial monolayer and transendothelial migration. For the invasion assay, HUVECs were inoculated at 2 9 10 5 cells per well of 8-well Lab-Tek chamber slides (Nunc, Naperville, IL, USA) pre-coated with type I collagen (40 lg ⁄ mL) and incubated for 3 days. T-24 cells that had been labeled with Cell Tracker Green or Orange (Lonza, Walkersville, MD, USA) were incubated on the HU-VEC monolayer for 18 h. Fluorescence images were obtained with BZ-8000 fluorescence microscope (Keyence, Osaka, Japan). For the transendothelial migration assay, fluorescencelabeled T-24 cells were incubated with test samples on the HUVEC monolayer prepared in culture inserts (8-lm pore size) for 18 h. Fluorescence images were obtained for the cells that had migrated onto the lower surface of membrane filters.
Immunofluorescent staining of cytoskeletal and membranebound proteins. The HUVECs were inoculated at 5 9 10 4 cells per well of a Lab-Tek 8-well chamber slide precoated with fibronectin (1 lg ⁄ mL) and grown to reach suitable density. After treatment with test samples, the cells were fixed in acetone ⁄ methanol (1:1, v ⁄ v) for 15 min on ice, blocked with 3% BSA in PBS for 1 h and incubated with primary antibody against a-tubulin, VE-cadherin, or b-catenin diluted with the blocking buffer. The cells were then stained with FITC-labeled secondary antibody, rhodamine phalloidin, and DAPI for 1 h. The fluorescence images were obtained using a confocal microscope (FV1000; Olympus, Tokyo, Japan).
Statistical analysis. Statistical significance was evaluated with an unpaired Student's t-test. A P-value < 0.05 was considered significant.
Results

Induction of morphological changes of endothelial cells by
Lmc2 chain. The Lmc2 chain is cleaved at a specific site of domain III in the short arm (c2SA) by some proteinases, releasing the N-terminal fragment, named c2pf (Fig. 1a) . It was previously found that c2SA has tumor-promoting activity in vivo. (28) To examine the biological activities of the c2 chain toward vascular endothelial cells, we prepared the full-length c2 and its various N-terminal fragments, including c2pf, c2dV, and c2SA (Fig. 1b) . Among them, c2pf and c2dV were mainly used in this study because of their high purity and relative importance. (36) When the growth effect of c2pf on endothelial cells (HUVECs) was examined, it showed a statistically significant but faint growth-stimulatory effect (Fig. 1c) . In the twochamber assay, c2pf scarcely stimulated the migration of HUVECs (Fig. S1a) . However, when c2pf was added to the monolayer culture of HUVECs, these cells became markedly retracted or shrunken compared with untreated cells (Fig. 1d) . Such a morphological change was not observed when the epithelial cell line MDCK was treated with c2pf (data not shown). We also confirmed that c2SA induced similar morphological changes in endothelial cells (Fig. S1b,c) . However, c2SA showed little growth effect on endothelial cells (data not shown).
We next examined the effects of Lmc2 on the interaction between cancer cells and endothelial cells, using the human bladder carcinoma cell line T-24 overexpressing c2SA (c2SA-T24) and its control cell line transfected with the empty vector (Mock-T24) (Fig. 2a) . These cell lines were labeled with fluorescence (Cell Tracer Orange) and then placed on the monolayer culture of HUVECs. Under a fluorescent microscope, Mock-T24 cells spread poorly on the HUVEC monolayer, whereas c2SA-T24 cells were well spread and extended many cell protrusions (Fig. 2b, upper panels, c) . When Mock-T24 cells were treated with purified c2pf protein, they showed a similar spreading morphology to that of c2SA-T24 cells (Fig. 2b, upper right panel, c) . The addition of c2pf dose-dependently promoted the protrusion formation of Mock-T24 cells (Fig. 2d) . Fluorescence labeling of cancer cells and filamentous actin staining of whole culture with rhodamine phalloidin revealed that both c2SA-T24 cells and the c2pf-treated Mock-T24 cells had invaded into the HUVEC monolayer and spread on the plastic surface (Fig. 2b, lower panels) .
Induction of transendothelial migration of cancer cells by Lmc2
chain. The results shown above suggested that c2pf might induce migration of cancer cells through the endothelial cell sheet. This was tested by the Transwell chamber assay. Fluorescence-labeled Mock-T24 cells were placed on the HUVEC monolayer in the upper chamber and incubated in the presence or absence of purified c2pf. The number of cells that migrated through the endothelial monolayer to the lower chamber increased 2.5 times in the presence of c2pf (Fig. 3a,b) . This clearly indicated that c2pf stimulated the cancer cell migration through the endothelial monolayer sheet.
Enhancement of vascular permeability by Lmc2 chain. The c2pf-induced retraction of endothelial cells seemed to lead to their loss of barrier integrity. To confirm this possibility, we examined the activity of c2pf on endothelial permeability in vitro (Fig. 4a) . When the monolayers of HUVECs on the culture inserts were treated with purified c2pf, the endothelial cell permeability, as measured by the diffusion of FITCdextran through the HUVEC sheet, significantly increased compared to the untreated control cultures. In addition, enhanced permeability was observed with the full-length c2 chain and its N-terminal domain V (c2dV) (Fig. 4b, see also  Fig. 1a) . The order of the permeability activity was c2dV > c2pf > full-length c2. Furthermore, we examined the effect of Lmc2 on vascular permeability in vivo by Miles permeability assay with mice (Fig. 5) . The intradermal injection of c2pf increased the leakage of Evans blue dye twofold compared to the PBS injection as control (Fig. 5a ). Purified c2dV also increased vascular permeability two-fold (Fig. 5b) , but domain III of Lmc2 did not show any significant activity (Figs 5c, S2, see also Fig. 1a) . These results suggest that the N-terminal fragments of Lmc2 chain function as vascular permeability-promoting factors in pathological conditions.
Rearrangement of cytoskeleton by c2pf in HUVECs. To elucidate the mechanism by which the laminin c2 chain disrupts the barrier function of vascular endothelial cells, we next examined effect of c2pf on the localization of cytoskeletal proteins and adherence junction proteins (Fig. 6) . In a sparse culture of HUVECs, double fluorescence staining of F-actin and microtubules showed that c2pf strongly induced actin stress fibers in the cytoplasm, while it reduced or disassembled microtubule structures (Fig. 6a) . As expected, the c2pf-induced actin stress fiber formation was effectively blocked by the treatment with the ROCK inhibitor Y-27632 (Fig. 6b) .
The induction of stress fiber formation by c2pf was also found in confluent culture of HUVECs (Fig. 6c) . Although VE-cadherin and b-catenin were localized linearly along with cell-cell borders in the untreated cells, this localization was disrupted or became unclear on treatment with c2pf (Fig. 6c,d) .
We also investigated effects of Lmc2 on major signal transduction for cytoskeletal regulation. The results showed that c2pf weakly activated ERK and p38 MAPK but inactivated Akt in HUVECs (Fig. S3) . 
Interaction of Lmc2 chain with membrane receptors on
HUVECs. It has previously been suggested that the c2 chain interacts with syndecan-1 and other anionic molecules on the cell surface. (36, 39) In the present analysis by cell ELISA, c2pf bound to the cell surface of HUVECs in a dose-dependent manner and this binding was blocked efficiently by the presence of heparin and completely by 1 M NaCl (Fig. S4) . We also attempted to identify the membrane receptors of the c2 chain on HUVECs. Experiments with a c2pf-conjugated column showed that it bound to HSPGs with a molecular mass range from 100 to 150 kDa as core proteins (Fig. S4a) . However, syndecan-1 was detected in neither the membrane fractions nor the column fractions (data not shown). Furthermore, pull-down assay with anti-His-tag antibody showed that c2pf interacted with membrane proteins with 50-75 kDa in addition to HSPGs (Fig. S4b) .
As shown in Figure 4(b) , the most N-terminal domain of Lmc2, domain V (c2dV) had the highest activity to stimulate the endothelial cell permeability. It is composed of three N-terminal EGF-like-repeats, that is, disulfide bond-linked loop structures (NE1, 2, and 3). To localize the active site in domain V, we prepared three combinations of two repeats, NE1 ⁄ 2, NE1 ⁄ 3, and NE2 ⁄ 3 (Fig. 7a) . In the pull-down assay with heparin-Sepharose, NE1 ⁄ 2 most strongly bound to heparin-Sepharose (Fig. 7b) . NE1 ⁄ 3 weakly bound to heparin but not NE2 ⁄ 3 at all. Moreover, NE1 ⁄ 2 most evidently induced the delocalization of VE-cadherin from the cell-cell borders, but NE2 ⁄ 3 did not (Fig. 7c) . Consistent with these results, NE1 ⁄ 2 increased vascular permeability in vivo more evidently than c2dV (Fig. 7d) . Neither NE1 ⁄ 3 nor NE2 ⁄ 3 showed significant activity. These data suggest that the first EGF-like repeat NE1 plays a critical role in the biological activities and heparin-binding activity of the Lmc2 chain.
Discussion
Dysfunctions of the vascular system in cancer tissues are strongly involved in cancer progression. For example, enhanced angiogenesis supports tumor growth and metastasis. (34, 35) Abnormal structures and loss of the barrier function of vasculature impair normal blood circulation. This causes hypoxia in cancer tissue and induces hypoxia-inducible factor1a, increasing the invasive potential of cancer cells. (40) The present study showed for the first time that the tumor invasion marker Lmc2 had profound activities toward vascular endothelial cells. Laminin c2 induced cytoskeletal changes and retraction of endothelial cells. These activities enhanced vascular permeability in vitro and in vivo and transendothelial migration of cancer cells through the endothelial cell sheet. Although we do not currently have direct evidence, our results suggest the hypothesis that Lmc2 produced by invading cancer cells acts on surrounding blood vessels and accelerates the abnormal vascular structure and functions as well as cancer progression. Recently we reported that expression of Lmc2 monomer in T-24 bladder carcinoma cells enhances their invasive growth and accumulation of ascites fluid when the cells are i.p. transplanted into nude mice. (28) These previous results support the above hypothesis. The stimulation of transendothelial migration of cancer cells by Lmc2 also suggests the possibility that it may enhance intravasation or extravasation of cancer cells, leading to the enhanced metastasis. Although this possibility was preliminarily tested, we failed to obtain enough evidence (data not shown). Laminin c2 scarcely stimulated the proliferation or migration of vascular endothelial cells. However, the disruption of the intercellular junction of endothelial cells is an important initial step of tumor angiogenesis. Therefore, it is also possible that Lmc2 may be involved in tumor angiogenesis. These possible functions of Lmc2 in cancer vasculature and cancer progression remain to be clarified in further studies.
In the Lm332 molecule, the short arm of Lmc2 has important effects on Lm332 activity. The loss of c2pf from Lm332 decreases cell adhesion activity and increases cell motility activity, (11) and the cell adhesion effect of c2pf is mediated by the interaction of domain V with syndecan-1 on the cell surface. (36) Moreover, domain IV of Lmc2 is critical for the matrix assembly of Lm332. (14) One research group showed that domain III of Lmc2, which is not contained in c2pf, is important for the cell motility activity of Lm332, and this active site is released by MMP2 and MT1-MMP. (13, 41) However, mammalian tolloid metalloproteinase (or BMP-1) has been shown to be a major c2pf-releasing enzyme. (12) In addition, matrilysin (MMP7) (42) and neutrophil elastase (43) have been reported to cleave Lmc2. The present study showed that c2pf could bind to some HSPGs and lower molecular weight proteins in the membrane fraction of HUVECs. Synecan-1 was undetectable even in the membrane fraction. The interaction between c2pf with HSPGs seems to be responsible for the biological activities of c2pf because heparin inhibited the interaction. Moreover, we found that NE1 of domain V in Lmc2 plays an essential role in Lmc2 activities. Interestingly, the activities toward HUVECs were highest in c2dV, then c2pf, and the full length Lmc2, in this order. Although c2dV and c2pf similarly increased vascular permeability in vivo, the NE1 ⁄ 2 fragment showed higher activity than c2dV. It is supposed that smaller fragments containing the active site NE1 may exert higher permeability activity than larger fragments. Laminin c2pf or similar fragments are produced from Lm332, the b3c2 dimer, and the c2 monomer. (15, 28, 29) Unidentified fragments of Lmc2 short arm have been detected in sera from patients with pancreatic cancers (30) and in squamous cell carcinomas. (44, 45) Laminin c2 is expressed by not only invading cancer cells but also cancer-associated fibroblasts. (46) Our preliminary analysis has shown that c2pf and smaller fragments containing domain V are indeed produced in invasive human cancer tissues (unpublished data, 2013). These results imply that domain V fragments are released by some proteinases in human cancer tissues. It seems very likely that the c2dV-containing fragments produced by invasive cancer cells and activated fibroblasts act on surrounding blood vessels.
The present study also showed that c2pf and c2dV strongly induced actin stress fiber formation, while diminishing microtubule structures. Moreover, c2pf and c2dV activated ERK and p38 MAP kinases, and Rho kinase was involved in the c2-mediated cytoskeletal changes of endothelial cells. These activities of Lmc2 and its N-terminal fragments seem to cause the retraction of endothelial cells and loosen the cell-cell junction, mediated by VE-cadherin. These activities of Lmc2 are similar to those of vascular endothelial growth factor. (47, 48) It is well known that the cell surface HSPG syndecans cooperate with integrins to induce actin cytoskeletal changes and regulate cell adhesion. (49, 50) It is very likely that the interaction of c2pf or c2dV with unidentified cell surface HSPGs induces similar cytoskeletal changes in vascular endothelial cells. In conclusion, the present study strongly suggests that Lmc2 or its N-terminal fragments produced in human cancer tissues are involved in aberrant vascular functions in cancer tissues.
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